Exelixis Inc. buy Quitte
Start price
01.03.16
/
50%
€3.78
Target price
25.04.16
€4.21
Performance (%)
11.80%
End price
25.04.16
€4.23
Summary
This prediction ended on 25.04.16 with a price of €4.23. The BUY prediction by Quitte finished with a performance of 11.80%. Quitte has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Exelixis Inc. | 4.402% | 4.402% | 30.189% | 180.563% |
| iShares Core DAX® | 1,50 % | -0,27 % | 5,21 % | 52,59 % |
| iShares Nasdaq 100 | 1,85 % | -0,07 % | 37,79 % | 90,51 % |
| iShares Nikkei 225® | 0,41 % | 4,08 % | 60,70 % | 76,93 % |
| iShares S&P 500 | 1,48 % | 0,78 % | 26,35 % | 66,80 % |
Comments by Quitte for this prediction
In the thread Exelixis Inc. diskutieren
gute Zahlen
Exelixis, Inc. (NASDAQ:EXEL) announced its quarterly earnings results on Monday. The biotechnology company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.03, MarketBeat reports. The company had revenue of $9.94 million for the quarter, compared to analyst estimates of $8.16 million. Exelixis’s revenue for the quarter was up 35.2% on a year-over-year basis. During the same period in the prior year, the business posted ($0.30) earnings per share.